New developments in the treatment of infective endocarditis (infective cardiovasculitis)

International Journal of Antimicrobial Agents

Volumn 13, Issue 2, 1999, Pages 79-92

  Gutschik, Ernö ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bacterial infection; Cardiovasculitis; Infective endocarditis; Treatment

Indexed keywords

CEFTRIAXONE; PENICILLIN G; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL ENDOCARDITIS; HEART VALVE SURGERY; HOSPITAL INFECTION; HUMAN; PRIORITY JOURNAL; REVIEW; VASCULITIS;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; ENDOCARDITIS, BACTERIAL; HISTORY, 20TH CENTURY; HUMANS; VASCULITIS;

EID: 0033213149     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00110-7     Document Type: Review

References (132)

1. Lerner P.I., Weinstein L. Infective endocarditis in the antibiotic era. N. Engl. J. Med. 274:1966;199-206.
2. Lerner P.I., Weinstein L. Infective endocarditis in the antibiotic era. N. Engl. J. Med. 274:1966;323-331.
3. Lerner P.I., Weinstein L. Infective endocarditis in the antibiotic era. N. Engl. J. Med. 274:1966;388-393.
4. Lerner P.I., Weinstein L. Infective endocarditis in the antibiotic era. N. Engl. J. Med. 274:1966;259-266.
5. Kaye D. Definitions and demographic characteristics. Kaye D. Infective Endocarditis. 1976;1-10 University Park Press, Baltimore, MD.
6. Kay J.H., Bernstein S., Feinstein D., Biddle M. Surgical cure of Candida albicans endocarditis with open-heart surgery. N. Engl. J. Med. 264:1961;907-910.
7. Von Reyn C.F., Levy B.S., Arbeit R.D., Friedland G., Crumpacker C.S. Infective endocarditis: an analysis based on strict case definitions. Ann. Intern. Med. 94:1981;505-518.
8. Durack D.T., Lukes A.S., Bright D.K. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am. J. Med. 96:1994;200-209. [see comments].
9. Loose R., Markant S., Sievers H.H., Bernhard A. Fate of endothelial cells during transport, cryopreservation, and thawing of heart valve allografts. Transplant. Proc. 25:1993;3247-3250.
10. Vogt PR, Künzli A, Lachat M, Zünd G, Niederhäuser U, Turina MI. Explanted cryopreserved homografts: a pathological and immunohistochemical comparison between arterial homografts and homograft cardiac valves from infants and adults. Programs and Abstracts of the 12th Annual Meeting of the European Association for Cardio-Thoracic Surgery. Bruxelles, 1998. Abstract 054.
11. Cremieux A.C., Carbon C. Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis. Antimicrob. Agents Chemother. 36:1992;2069-2074.
12. Gutschik E. Experimental staphylococcal endocarditis: an overview. Scand. J. Infect. Dis. Suppl. 41:1983;87-94.
13. Gutschik E. The Enterococcus endocarditis model in experimental animals and its relevance to human infection. J. Antimicrob. Chemother. 31((Suppl D)):1993;87-95.
14. Fluckiger U., Moreillon P., Blaser J., Bickle M., Glauser M.P., Francioli P. Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats. Antimicrob. Agents Chemother. 38:1994;2846-2849.
15. Weinstein L., Brusch Y.L. Medical managements. Weinstein L., Brusch Y.L. Infective Endocarditis. 1996;256-304 Oxford University Press, New York.
16. Working Party of the British Society for Antimicrobial Chemotherapy Antibiotic treatment of streptococcal, enterococcal, and staphylococcal endocarditis. Heart. 79:1998;207-210.
17. The Endocarditis Working Group of the International Society for Chemotherapy , Wilson W.R. Antibiotic treatment of infective endocarditis due to viridans streptococci, enterococci, and other streptococci. Clin. Microbiol. Infect. 4:1998;3S17-3S26.
18. Pollock A.A., Tee P.E., Patel I.H., Spicehandler J., Simberkoff M.S., Rahal J.J.J. Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults. Antimicrob. Agents Chemother. 22:1982;816-823.
19. Francioli P., Etienne J., Hoigne R., Thys J.P., Gerber A. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. J. Am. Med. Assoc. 267:1992;264-267.
20. Core Data Sheet. Ceftriaxon. (1.2). Basel: Roche, 1997.
21. Calain P., Krause K.H., Vaudaux P. et al. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J. Infect. Dis. 155:1987;187-191.
22. Hedstrom SA. Teicoplanin vs. vancomycin in severe Gram-positive infection - a multicentre Scandinavian trial. 7th European Congress of Clinical Microbiology and Infectious Diseases, 1995. Abstract nr. 760.
23. Prins J.M., Buller H.R., Kuijper E.J., Tange R.A., Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 341:1993;335-339.
24. Gilbert D.N. Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides. Clin. Infect. Dis. 24:1997;816-819.
25. Cremieux A.C., Maziere B., Vallois J.M. et al. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J. Infect. Dis. 159:1989;938-944.
26. Bayer A.S., Crowell D., Nast C.C., Norman D.C., Borrelli R.L. Intravegetation antimicrobial distribution in aortic endocarditis analyzed by computer-generated model. Implications for treatment. Chest. 97:1990;611-617.
27. Bugnon D., Potel G., Xiong Y.Q. et al. In vivo antibacterial effects of simulated human serum profiles of once- daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model. Antimicrob. Agents Chemother. 40:1996;1164-1169.
28. Francioli P., Ruch W., Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin. Infect. Dis. 21:1995;1406-1410.
29. Sexton D.J., Tenenbaum M.J., Wilson W.R. et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin. Infect. Dis. 27:1998;1470-1474.
30. Fantin B., Carbon C. In vivo antibiotic synergism: contribution of animal models. Antimicrob. Agents Chemother. 36:1992;907-912.
31. Saleh-Mghir A., Cremieux A.C., Vallois J.M., Muffat-Joly M., Devine C., Carbon C. Optimal aminoglycoside dosing regimen for penicillin-tobramycin synergism in experimental Streptococcus adjacens endocarditis. Antimicrob. Agents Chemother. 36:1992;2403-2407.
32. Brandt C.M., Warner C.B., Rouse M.S., Steckelberg J.M., Wilson W.R. Effect of gentamicin dosing interval on efficacy of penicillin or ceftriaxone treatment of experimental endocarditis due to penicillin- susceptible, ceftriaxone-tolerant viridans group streptococci. Antimicrob. Agents Chemother. 40:1996;2901-2903.
33. Blatter M., Fluckiger U., Entenza J., Glauser M.P., Francioli P. Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis. Antimicrob. Agents Chemother. 37:1993;1971-1976.
34. Carbon C. Impact of the antiobiotic dosage schedule on efficay in experimental endocarditis. Scand. J. Infect. Dis. Suppl. 74:1991;163-172.
35. Fantin B., Carbon C. Importance of the aminoglycoside dosing regimen in the penicillin- netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis. Antimicrob. Agents Chemother. 34:1990;2387-2391.
36. Hessen M.T., Pitsakis P.G., Levison M.E. Absence of a postantibiotic effect in experimental Pseudomonas endocarditis treated with imipenem, with or without gentamicin. J. Infect. Dis. 158:1988;542-548.
37. Hessen M.T., Pitsakis P.G., Levison M.E. Postantibiotic effect of penicillin plus gentamicin versus Enterococcus faecalis in vitro and in vivo. Antimicrob. Agents Chemother. 33:1989;608-611.
38. Wilson W.R., Geraci J.E. Antimicrobial therapy for penicillin-sensitive streptococcal infective endocarditis: two-week regimens. Bisno A.L. Treatment of Infective Endocarditis. 1981;61-73 Grune & Stratton, Inc, New York.
39. Moellering R.C.J. Antimicrobial susceptibility of enterococci: In vitro studies of the action of antibiotics alone and in combination. Bisno A.L. Treatment of Infective Endocarditis. 1981;81-96 Grune & Stratton, Inc, New York.
40. Roberts S.A., Lang S.D.R., Ellis-Pegler S.B. Short-course treatment of penicillin susceptible viridans streptococcal infective endocarditis with penicillin and gentamicin. Infect. Dis. Clin. Pract. 2:1993;191-194.
41. The Endocarditis Working Group of the International Society for Chemotherapy , Gutschik E. Microbiological recommendations for the diagnosis and follow-up of infective endocarditis. Clin. Microbiol. Infect. 4:1998;3S10-3S16.
42. Geraci J.E., Martin W.J. Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis: clinical, pathologic and therapeutic considerations of 33 cases. Circulation. 10:1954;173-194.
43. Gutschik E., Mortensen I., Moller S. Experimental endocarditis in rabbits. 5. Results of long-term penicillin or streptomycin treatment of streptococcus faecalis endocarditis and the effect of long-term exposure of healthy rabbits to the same drugs. Acta. Pathol. Microbiol. Immunol. Scand. [B]. 90:1982;25-35.
44. Gutschik E. Experimental endocarditis in rabbits. 6. Results of long-term combined therapy of Streptococcus faecalis endocarditis with penicillin and streptomycin. Acta. Pathol. Microbiol. Immunol. Scand. [B]. 90:1982;37-47.
45. Gutschik E. Experimental endocarditis in rabbits. 7. Results of long-term combined therapy of Streptococcus faecalis endocarditis with penicillin and gentamicin. Acta. Pathol. Microbiol. Immunol. Scand. [B]. 90:1982;295-302.
46. Eliopoulos G.M. Enterococcal endocarditis. Kaye D. Infective Endocarditis. 1992;209-223 Raven Press, Ltd, New York.
47. Matsumoto J.Y., Wilson W.R., Wright A.J., Geraci J.E., Washington J.A. Synergy of penicillin and decreasing concentration of aminoglycosides against enterococci from patients with infective endocarditis. Antimicrob. Agents Chemother. 18:1980;944-947.
48. Wright A.J., Wilson W.R., Matsumoto J.Y., Washington J.A., Geraci J.E. Influence of gentamicin dose size on the efficacies of combinations of gentamicin and penicillin in experimental streptomycin-resistant enterococcal endocarditis. Antimicrob. Agents Chemother. 22:1982;972-975.
49. Dlaison L, Hogevik H, Alestig K. Shortened duration of combined aminoglycoside synergistic therapy in enterococcal endocarditis. Proceedings of the 3rd Nordic-Baltic Congress on Infectious Diseases. Anonymous. Vilnius, Lithuania: 1998. p. 67.
50. Wilson W.R., Wilkowske C.J., Wright A.J., Sande M.A., Geraci J.E. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann. Intern. Med. 100:1984;816-823.
51. Eliopoulos G.M. Aminoglycoside resistant enterococcal endocarditis. Infect. Dis. Clin. North Am. 7:1993;117-133.
52. Korzeniowski O., Sande M.A. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann. Intern. Med. 97:1982;496-503.
53. Mortara L.A., Bayer A.S. Staphylococcus aureus bacteremia and endocarditis. New diagnostic and therapeutic concepts. Infect. Dis. Clin. North Am. 7:1993;53-68.
54. Godtfredsen W.O., Roholt K., Tybring L. Fucidin: a new orally active antibiotic. Lancet. 1:1962;928-931.
55. Fantin B., Leclercq R., Duval J., Carbon C. Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1993;2466-2469.
56. Haag R. Efficacy of penicillin G, flucloxacillin, cefazolin, fusidic acid, vancomycin, rifampicin and fosfomycin in muscular infections in mice due to Staphylococcus aureus. Infection. 14:1986;38-43.
57. Roder B.L., Forsgren A., Gutschik E. The effect of antistaphylococcal agents used alone and in combinations on the survival of Staphylococcus aureus ingested by human polymorphonuclear leukocytes. APMIS. 99:1991;521-529.
58. Nielsen S.L., Black F.T. The effect of dicloxacillin and fusidic acid on the extracellular and intracellular killing of Staphylococcus aureus. J. Antimicrob. Chemother. 42:1998;221-226.
59. Zimmerli W., Widmer A.F., Blatter M., Frei R., Ochsner P.E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. J. Am. Med. Assoc. 279:1998;1537-1541.
60. Zavasky D.M., Sande M.A. Reconsideration of rifampin: a unique drug for a unique infection. J. Am. Med. Assoc. 279:1998;1575-1577.
61. Mandell G.L., Vest T.K. Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies. J. Infect. Dis. 125:1972;486-490.
62. Williams K.J., Piddock L.J. Accumulation of rifampicin by Escherichia coli and Staphylococcus aureus. J. Antimicrob. Chemother. 42:1998;597-603.
63. Zak O., Scheld W.M., Sande M.A. Rifampin in experimental endocarditis due to Staphylococcus aureus in rabbits. Rev. Infect. Dis. 5(Suppl 3):1983;S481-S490.
64. Gottlieb T., Mitchell D. The independent evolution of resistance to ciprofloxacin, rifampicin, and fusidic acid in methicillin-resistant Staphylococcus aureus in Australian teaching hospitals (1990-1995). Australian Group for Antimicrobial Resistance (AGAR). J. Antimicrob. Chemother. 42:1998;67-73.
65. Scheel O., Lyon D.J., Rosdahl V.T., Adeyemi-Doro F.A., Ling T.K., Cheng A.F. In-vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988-1993. J. Antimicrob. Chemother. 37:1996;243-251. [published erratum appears in J Antimicrob Chemother 1996 Nov;38(5):919].
66. Jarlov J.O. Phenotypic characteristics of coagulase-negative staphylococci: typing and antibiotic susceptibility. APMIS Suppl. Thesis. 91:1999;1-42.
67. Yeaman M.R., Bayer A.S. Treatment of experimental and human bacterial endocarditis with quinolone antimicrobial agents. Hooper D.C., Wolfson J.S. Quinolone Antimicrobial Agents. 1993;397-411 American Society for Microbiology, Washington, DC.
68. Humphreys H., Mulvihill E. Ciprofloxacin-resistant Staphylococcus aureus. Lancet. 2:1985;383.
69. Kaatz G.W., Barriere S.L., Schaberg D.R., Fekety R. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. J. Antimicrob. Chemother. 20:1987;753-758.
70. Roder B.L., Gutschik E. In-vitro activity of ciprofloxacin combined with either fusidic acid or rifampicin against Staphylococcus aureus. J. Antimicrob. Chemother. 23:1989;347-352. [see comments].
71. Bahl D., Miller D.A., Leviton I. et al. In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin- susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 41:1997;1293-1297.
72. Chambers H.F. Short-course combination and oral therapies of Staphylococcus aureus endocarditis. Infect. Dis. Clin. North Am. 7:1993;69-80.
73. Heldman A.W., Hartert T.V., Ray S.C. et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am. J. Med. 101:1996;68-76.
74. Kim Y.S., Liu Q., Chow L.L., Chambers H.F., Tauber M.G. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 42:1998;3325-3327.
75. South R. Retrospective study of teicoplanin as home continuation of hospital-initiated therapy. Int. J. Antimicrob. Agents. 9:1998;219-225.
76. Nathwani D., Conlon C. On behalf of the OHPAT UK Workshop: outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party. Clin. Microbiol. Infect. 4:1998;537-551.
77. The Endocarditis Working Group of the International Society for Chemotherapy , Francioli P.B., Stamboulian D. Outpatient treatment of infective endocarditis. Clin. Microbiol. Infect. 4:1998;3S47-3S55.
78. Steckelberg J.M., Murphy J.G., Ballard D. et al. Emboli in infective endocarditis: the prognostic value of echocardiography. Ann. Intern. Med. 114:1991;635-640.
79. The Endocarditis Working Group of the International Society for Chemotherapy , Rubinstein E., Carbon C. Staphylococcal endocarditis - recommendations for therapy. Clin. Microbiol. Infect. 4:1998;3S27-3S33.
80. Shanson D.C. New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis. J. Antimicrob. Chemother. 42:1998;292-296.
81. Doern G.V., Ferraro M.J., Brueggemann A.B., Ruoff K.L. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob. Agents Chemother. 40:1996;891-894.
82. Renneberg J., Niemann L.L., Gutschik E. Antimicrobial susceptibility of 278 streptococcal blood isolates to seven antimicrobial agents. J. Antimicrob. Chemother. 39:1997;135-140.
83. Karchmer A.W. Issues in the treatment of endocarditis caused by viridans streptococci. Bisno A.L. Treatment of Infective Endocarditis. 1981;31-59 Grune & Stratton, Inc, New York
84. Moellering R.C.J. Treatment of endocarditis caused by resistant streptococci. Horstkotte D., Bodnar E. Infective Endocarditis. 1991;ICR Publishers, Aylesbury, Bucks, UK.
85. NCCLS. Performance Standards for Antimicrobial Susceptibility Testing; Eight Informational Supplement. M100-S8 1998. p. 17.
86. Group-European , Felmingham D., Brown D.-J.F., Soussy C.J. Glycopeptide Resistance Survey Study. European glycopeptide susceptibility survey of gram-positive bacteria for 1995. Diagn. Microbiol. Infect. Dis. 31:1998;563-571.
87. Gruneberg R.N., Hryniewicz W. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin. Int. J. Antimicrob. Agents. 10:1998;271-277.
88. Fantin B., Leclercq R., Arthur M., Duval J., Carbon C. Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium. Antimicrob. Agents Chemother. 35:1991;1570-1575.
89. Johnson A.P., Warner M., Woodford N., Speller D.C., Livermore D.M. Antibiotic resistance among enterococci causing endocarditis in the UK: analysis of isolates referred to a reference laboratory. Br. Med. J. 317:1998;629-630.
90. Bryskier A. Novelties in the field of anti-infectives in 1997. Clin. Infect. Dis. 27:1998;865-883.
91. Entenza JM, Giddey M, Glauser MP, Moreillon P. Efficacy of the novel quinolone BAY 12-8039 (moxifloxacin) in the treatment of experimental endocarditis (EE) due to ciprofloxacin-susceptible (CIP-S) and ciprofloxacin-resistant (CIP-R), methicillin-resistant Staphylococcus aureus (MRSA). Proceedings of the 38th Annual ICAAC. San Diego, CA, 1998. p. 67 (Abstract).
92. Reinert R.R., Bryskier A., Lutticken R. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany. Antimicrob. Agents Chemother. 42:1998;1509-1511.
93. Schulin T., Wennersten C.B., Moellering R.C.J., Eliopoulos G.M. In-vitro activity of the new ketolide antibiotic HMR 3647 against gram- positive bacteria. J. Antimicrob. Chemother. 42:1998;297-301.
94. Saleh-Mghir A., Lefort A., Petegnief Y. et al. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 43:1999;115-120.
95. Kaatz G.W., Seo S.M., Aeschlimann J.R., Houlihan H.H., Mercier R.C., Rybak M.J. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 42:1998;981-983.
96. Zhanel G.G., Kirkpatrick I.D., Hoban D.J., Kabani A.M., Karlowsky J.A. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 42:1998;2427-2430.
97. Pechere J.C. Streptogramins. A unique class of antibiotics. Drugs. 51(Suppl 1):1996;13-19.
98. Mouton J.W., Endtz H.P., den Hollander J.G., van den Braak N., Verbrugh H.A. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis. J. Antimicrob. Chemother. 39(Suppl A):1997;75-80.
99. Carbon C. Quinupristin/dalfopristin: a review of its activity in experimental animal models of infection. J. Antimicrob. Chemother. 39(Suppl A):1997;115-119.
100. Fantin B., Leclercq R., Garry L., Carbon C. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob. Agents Chemother. 41:1997;931-935.
101. B-R). Programs and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 1998. p. 67 (Abstract).
102. Leclercq R., Courvalin P. Streptogramins: an answer to antibiotic resistance in gram-positive bacteria. Lancet. 352:1998;591-592.
103. Larkin J., Busciglio L., Fontanet H., Gamouras G. Staphylococcus epidermidis endocarditis treated with RP 59500 (quinapristin/dalfopristin). Clin. Infect. Dis. 26:1998;1239-1240.
104. Rybak M.J., Cappelletty D.M., Moldovan T., Aeschlimann J.R., Kaatz G.W. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU- 100766) versus vancomycin against Staphylococcus aureus, coagulase- negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob. Agents Chemother. 42:1998;721-724.
105. Dresser L.D., Rybak M.J. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy. 18:1998;456-462.
106. Nakashio S., Iwasawa H., Dun F.Y., Kanemitsu K., Shimada J. Everninomicin, a new oligosaccharide antibiotic: its antimicrobial activity, post-antibiotic effect and synergistic bactericidal activity. Drugs Exp. Clin. Res. 21:1995;7-16.
107. Aarestrup F.M. Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomicin (SCH 27899), and resistance to an antibiotic used for growth promotion in animals, avilamycin. Microb. Drug Resist. 4:1998;137-141.
108. Dhawan VK, Yeaman MR, Bayer AS. Thrombin-induced platelet microbial protein (tPMP) susceptibility phenotype influences the treatment outcome in experimental Staphylococcus aureus (SA) endocarditis (IE). Programs and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract B-73.
109. Yeaman M.R., Soldan S.S., Ghannoum M.A., Edwards J.E.J., Filler S.G., Bayer A.S. Resistance to platelet microbicidal protein results in increased severity of experimental Candida albicans endocarditis. Infect. Immun. 64:1996;1379-1384.
110. Miyasaki K.T., Lehrer R.I. Beta-sheet antibiotic peptides as potential dental therapeutics. Int. J. Antimicrob. Agents. 9:1998;269-280.
111. Chikindas M.L., Novak J., Caufield P.W., Schilling K., Tagg J.R. Microbially-produced peptides having potential application to the prevention of dental caries. Int. J. Antimicrob. Agents. 9:1997;95-105.
112. The Endocarditis Working Group of the International Society for Chemotherapy , Pettersson G., Carbon C. Recommendations for the surgical treatment of endocarditis. Clin. Microbiol. Infect. 4:1998;3S34-3S46.
113. Tingleff J., Egeblad H., Gotzsche C.O. et al. Perivalvular cavities in endocarditis: abscesses versus pseudoaneurysms? A transesophageal Doppler echocardiographic study in 118 patients with endocarditis. Am. Heart. J. 130:1995;93-100.
114. Wernly J.A., Crawford M.H. Choosing a prosthetic heart valve. Cardiol. Clin. 16:1998;491-504.
115. Ely J.L., Emken M.R., Accuntius J.A. et al. Pure pyrolytic carbon: preparation and properties of a new material, On- X carbon for mechanical heart valve prostheses. J. Heart Valve. Dis. 7:1998;626-632.
116. Mackay T.G., Wheatley D.J., Bernacca G.M., Fisher A.C., Hindle C.S. New polyurethane heart valve prosthesis: design, manufacture and evaluation. Biomaterials. 17:1996;1857-1863.
117. Menzler F., Haubold A.D., Hwang N.H. Dynamic characterization of a new accelerated heart valve tester. ASAIO J. 43:1997;M372-M377.
118. Fenner J.W., Mackay T.G., Martin W., Wheatley D.J. Laser profiling: a technique for the study of prosthetic heart valve leaflet motion. Physiol. Meas. 16:1995;181-193.
119. Joyce F., Tingleff J., Pettersson G. The Ross operation: results of early experience including treatment for endocarditis. Eur. J. Cardiothorac. Surg. 9:1995;384-391.
120. Kjaergard H.K., Fairbrother J.E., Cederholm-Williams S.A., Edwardson P.A.D., Hollingsbee D.A., Holm N.-E. The vivostat system for the automated preparation of autologous fibrin sealant. Cardiovasc. Eng. 2:1997;1-3.
121. Thompson D.F., Letassy N.A., Thompson G.D. Fibrin glue: a review of its preparation, efficacy, and adverse effects as a topical hemostat. Drug Intell. Clin. Pharm. 22:1988;946-952.
122. Karck M., Siclari F., Wahlig H., Sperling U., Schmid C., Haverich A. Pretreatment of prosthetic valve sewing-ring with the antibiotic/fibrin sealant compound as a prophylactic tool against prosthetic valve endocarditis. Eur. J. Cardiothorac. Surg. 4:1990;142-146.
123. Watanabe G., Haverich A., Speier R., Dresler C., Borst H.G. Surgical treatment of active infective endocarditis with paravalvular involvement. J. Thorac. Cardiovasc. Surg. 107:1994;171-177.
124. French B.G., Wilson K., Wong M., Smith S., O'Brien M.F. Rifampicin antibiotic impregnation of the St. Jude Medical mechanical valve sewing ring: a weapon against endocarditis. J. Thorac. Cardiovasc. Surg. 112:1996;248-252. [see comments].
125. Actis D.G., Cavaglia M., Poletti G.A. Impregnation of sewing ring with antibiotics to avoid prosthetic valve endocarditis. J. Thorac. Cardiovasc. Surg. 114:1997;145-146. [letter; comment].
126. Tweden K.S., Cameron J.D., Razzouk A.J. et al. Silver modification of polyethylene terephthalate textiles for antimicrobial protection. ASAIO J. 43:1997;M475-M481.
127. Tweden K.S., Cameron J.D., Razzouk A.J., Holmberg W.R., Kelly S.J. Biocompatibility of silver-modified polyester for antimicrobial protection of prosthetic valves. J. Heart Valve. Dis. 6:1997;553-561.
128. Schierholz J.M., Lucas L.J., Rump A., Pulverer G. Efficacy of silver-coated medical devices. J. Hosp. Infect. 40:1998;257-262.
129. Terada Y., Mitsui T., Yamamoto T. Bacterial colonies around the suture material in bacteremia with a valve prosthesis. Ann. Thorac. Surg. 58:1994;911. [letter].
130. Horstkotte D., Weist K., Ruden H. Better understanding of the pathogenesis of prosthetic valve endocarditis - recent perspectives for prevention strategies. J. Heart Valve. Dis. 7:1998;313-315. [editorial; comment].
131. Zachary I. Vascular endothelial growth factor. Int. J. Biochem. Cell. Biol. 30:1998;1169-1174.
132. Carlyle WC, Kelly SJ, Ogle MF, Mirsch W. Accelerated endothelialization of bioprosthetic heart valve leaflets with vascular endothelial growth factor. Programs and Abstracts of the 71th American Heart Association Scientific Sessions 1998. Abstract 1708.